Reviewing Achilles Therapeutics (NASDAQ:ACHL) & Immunocore (NASDAQ:IMCR)

Achilles Therapeutics (NASDAQ:ACHL) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Achilles Therapeutics and Immunocore, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achilles Therapeutics	0	0	0	0	0.00
Immunocore	1	3	7	0	2.55

Immunocore has a consensus target price of $58.89, indicating a potential upside of 69.81%. Given Immunocore’s stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than Achilles Therapeutics.

Volatility & Risk

Achilles Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Earnings and Valuation

This table compares Achilles Therapeutics and Immunocore”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achilles Therapeutics	N/A	N/A	-$69.67 million	($1.65)	-0.90
Immunocore	$333.58 million	5.22	-$55.29 million	($0.43)	-80.65

Immunocore has higher revenue and earnings than Achilles Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Achilles Therapeutics and Immunocore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Achilles Therapeutics	N/A	-54.45%	-47.68%
Immunocore	-15.87%	-12.84%	-5.09%

Insider and Institutional Ownership

56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Immunocore beats Achilles Therapeutics on 10 of the 13 factors compared between the two stocks.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.